Literature DB >> 24664786

Topical microbicides and HIV prevention in the female genital tract.

Mackenzie L Cottrell1, Angela D M Kashuba.   

Abstract

Worldwide, HIV disproportionately affects women who are often unable to negotiate traditional HIV preventive strategies such as condoms. In the absence of an effective vaccine or cure, chemoprophylaxis may be a valuable self-initiated alternative. Topical microbicides have been investigated as one such option. The first generation topical microbicides were non-specific, broad-spectrum antimicrobial agents, including surfactants, polyanions, and acid buffering gels, that generally exhibited contraceptive properties. After extensive clinical study, none prevented HIV infection, and their development was abandoned. Second generation topical microbicides include agents with selective mechanisms of antiviral activity. Most are currently being used for, or have previously been explored as, drugs for treatment of HIV. The most advanced of these is tenofovir 1% gel: the first topical agent shown to significantly reduce HIV infection by 39% compared to placebo. This review summarizes the evolution of topical microbicides for HIV chemoprophylaxis, highlights important concepts learned, and offers current and future considerations for this area of research.
© 2014, The American College of Clinical Pharmacology.

Entities:  

Keywords:  HIV prevention; female genital tract; microbicide; pre-exposure prophylaxis; tenofovir gel

Mesh:

Substances:

Year:  2014        PMID: 24664786      PMCID: PMC4144014          DOI: 10.1002/jcph.292

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  80 in total

1.  High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women.

Authors:  A van der Straten; E T Montgomery; H Cheng; L Wegner; G Masenga; C von Mollendorf; L Bekker; S Ganesh; K Young; J Romano; A Nel; C Woodsong
Journal:  AIDS Behav       Date:  2012-10

2.  Reformulated tenofovir gel for use as a dual compartment microbicide.

Authors:  Charlene S Dezzutti; Lisa C Rohan; Lin Wang; Kevin Uranker; Cory Shetler; Marilyn Cost; J D Lynam; David Friend
Journal:  J Antimicrob Chemother       Date:  2012-05-11       Impact factor: 5.790

Review 3.  Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.

Authors:  Joseph Romano; Angela Kashuba; Stephen Becker; James Cummins; Jim Turpin; Fulvia Veronese
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-22       Impact factor: 2.205

4.  Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.

Authors:  Salim S Abdool Karim; Angela D M Kashuba; Lise Werner; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

5.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Authors:  Lut Van Damme; Gita Ramjee; Michel Alary; Bea Vuylsteke; Verapol Chandeying; Helen Rees; Pachara Sirivongrangson; Léonard Mukenge-Tshibaka; Virginie Ettiègne-Traoré; Charn Uaheowitchai; Salim S Abdool Karim; Benoît Mâsse; Jos Perriëns; Marie Laga
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

6.  Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men.

Authors:  Vicky Jespers; Anne Buvé; Lut Van Damme
Journal:  Sex Transm Dis       Date:  2007-07       Impact factor: 2.830

7.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

Authors:  Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber
Journal:  Lancet       Date:  2010-09-17       Impact factor: 79.321

8.  Safety of single daily use for one week of C31G HEC gel in women.

Authors:  S A Ballagh; J M Baker; D M Henry; D F Archer
Journal:  Contraception       Date:  2002-11       Impact factor: 3.375

9.  Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes.

Authors:  J Kreiss; E Ngugi; K Holmes; J Ndinya-Achola; P Waiyaki; P L Roberts; I Ruminjo; R Sajabi; J Kimata; T R Fleming
Journal:  JAMA       Date:  1992 Jul 22-29       Impact factor: 56.272

10.  Studies of nonoxynol-9. I. The effect on the vaginas of rabbits and rats.

Authors:  M Chvapil; W Droegemueller; J A Owen; C D Eskelson; K Betts
Journal:  Fertil Steril       Date:  1980-04       Impact factor: 7.329

View more
  10 in total

Review 1.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

Review 2.  The role of human dendritic cells in HIV-1 infection.

Authors:  Zahra Ahmed; Tatsuyoshi Kawamura; Shinji Shimada; Vincent Piguet
Journal:  J Invest Dermatol       Date:  2014-11-19       Impact factor: 8.551

Review 3.  Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.

Authors:  David N Burns; Cynthia Grossman; Jim Turpin; Vanessa Elharrar; Fulvia Veronese
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

4.  Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026).

Authors:  José A Bauermeister; Ryan C Tingler; Clara Dominguez; Eileen F Dunne; Craig Hoesley; Ken Ho; Sherri Johnson; Jonathan Lucas; Nicole Macagna; Elizabeth Brown; Holly Gundacker; Melissa Peda; Cindy E Jacobson; Lindsay Kramzer; Devika Singh; Charlene S Dezzutti; Ratiya Pamela Kunjara Na Ayudhya; Mark A Marzinke; Jeanna Piper; Bríd Devlin; Jeremy Nuttall; Ian McGowan; Craig W Hendrix; Ross D Cranston
Journal:  AIDS Behav       Date:  2021-10-17

5.  Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.

Authors:  Tian Zhou; Minlu Hu; Andrew Pearlman; Lisa C Rohan
Journal:  Biochem Pharmacol       Date:  2016-07-21       Impact factor: 5.858

Review 6.  Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses.

Authors:  Sahar G Eid; Niamh E Mangan; Paul J Hertzog; Johnson Mak
Journal:  Clin Transl Immunology       Date:  2015-10-09

7.  Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action.

Authors:  Rafael Ceña-Diez; Enrique Vacas-Córdoba; Pilar García-Broncano; F J de la Mata; Rafael Gómez; Marek Maly; M Ángeles Muñoz-Fernández
Journal:  Int J Nanomedicine       Date:  2016-05-19

8.  Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.

Authors:  Andrea Ries Thurman; Neelima Chandra; Nazita Yousefieh; Thomas Kimble; Sharon M Anderson; Mackenzie Cottrell; Craig Sykes; Angela Kashuba; Jill L Schwartz; Gustavo F Doncel
Journal:  J Acquir Immune Defic Syndr       Date:  2018-05-01       Impact factor: 3.731

9.  Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.

Authors:  Andrea R Thurman; Jacques Ravel; Pawel Gajer; Mark A Marzinke; Louise A Ouattara; Terry Jacot; M Melissa Peet; Meredith R Clark; Gustavo F Doncel
Journal:  Front Cell Infect Microbiol       Date:  2022-03-08       Impact factor: 5.293

10.  Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semen.

Authors:  Rafael Ceña-Diez; Pilar García-Broncano; Francisco Javier de la Mata; Rafael Gómez; M Ángeles Muñoz-Fernández
Journal:  Int J Nanomedicine       Date:  2016-05-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.